CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 36 enrolled
Drug / intervention
Blinatumomab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02458014
NCT02458014Phase 2Completed
CompareCT.gov

Phase II Study of Blinatumomab in Patients With B-Cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease

M.D. Anderson Cancer Center·interventional·Posted May 29, 2015·Updated Sep 23, 2025

In Brief

A Phase 2 clinical trial evaluating Blinatumomab and Laboratory Biomarker Analysis for Adult Acute Lymphoblastic Leukemia in Complete Remission and 3 related conditions. Completed, enrolled 36 participants across 1 site.

Detailed Summary

This phase II trial studies how well blinatumomab works in treating patients with B-cell acute lymphoblastic leukemia whose disease is in remission (causes no symptoms or signs) but is still present in a small number of cells in the body (minimal residual disease). Immunotherapy with monoclonal antibodies, such as blinatumomab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Acute Lymphoblastic Leukemia in Complete Remission, B Acute Lymphoblastic Leukemia, Minimal Residual Disease, Philadelphia Chromosome Positive
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 29, 2015
Enrollment StartSep 14, 2015
Primary CompletionSep 16, 2025
TodayJul 1, 2026
Enrollment to primary: 10.0 yearsPosted 11.1 years ago

Interventions

Blinatumomabbiological

Given IV

Laboratory Biomarker Analysisother

Correlative studies